
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 11, 2026

Tenaya Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-40656
(Commission File Number)

81-3789973
(IRS Employer
Identification No.)

**171 Oyster Point Boulevard
Suite 500
South San Francisco, California**
(Address of Principal Executive Offices)

94080
(Zip Code)

Registrant's Telephone Number, Including Area Code: (650) 825-6990

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.0001 per share	TNYA	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

On March 11, 2026, Tenaya Therapeutics, Inc. issued a press release announcing its financial results for the quarter and full year ended December 31, 2025 (“Earnings Press Release”). The full text of the Earnings Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release of Tenaya Therapeutics, Inc., dated March 11, 2026
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TENAYA THERAPEUTICS, INC.

By: /s/ Jennifer Drimmer Rokovich
Jennifer Drimmer Rokovich
General Counsel and Secretary

Date: March 11, 2026



Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory Alignment for Each Program Planned in 2026

New Research Supports TN-301's Potential in Multiple Indications; Presented Preclinical Data for TN-301 in Duchenne Muscular Dystrophy Model

Entered into Multi-Target Research Collaboration with Alnylam Pharmaceuticals

December Financing with Net Proceeds of \$55.8M and Anticipated Upfront Payment Extend Cash Runway into Second Half of 2027

SOUTH SAN FRANCISCO, Calif., March 11, 2026 –Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update.

“As we enter 2026, we are energized by the momentum and clinical advances achieved over the past year,” said Faraz Ali, Chief Executive Officer of Tenaya. “The encouraging data presented in 2025 from both of our lead gene therapy programs underscore the transformative potential of our science. In the first half of 2026, we expect to share additional updates, including longer-term follow-up data from the MyPEAK™-1 clinical trial of TN-201 for *MYBPC3-associated* HCM, as well as one-year Cohort 1 data and early Cohort 2 data from the RIDGE™-1 clinical trial of TN-401 for *PKP2-associated* ARVC. Over the course of the year, we also plan to pursue regulatory agency alignment on pivotal trial plans for both programs, a critical step toward accelerating the delivery of safe and effective gene therapies to patients with serious cardiac conditions.”

Mr. Ali continued, “We are also excited to take modest but important steps to move TN-301 -- our clinical-stage, highly selective, small molecule HDAC6 inhibitor -- forward towards patients. New preclinical data in relevant DMD models that we presented at the recent MDA meeting adds to a growing body of external evidence supporting the potentially broad clinical utility of TN-301 in a range of cardiac and cardiac-adjacent indications with high unmet patient need and large market potential. The recently announced Alnylam collaboration further validates our platform capabilities that originally led to the discovery of TN-301. Together, these developments reflect the potential for Tenaya to add exciting new value drivers that are orthogonal to our portfolio of genetic medicines.”

Business and Program Updates

TN-201 – Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy (HCM)

- In November 2025, Tenaya presented promising data from the MyPEAK-1 Phase 1b/2 clinical trial for the potential treatment of HCM due to *MYBPC3* mutations. The interim data reported

included safety, biopsy and leading indicators of efficacy results for the three patients who each received a 3E13 vg/kg dose (Cohort 1) with follow-up ranging from Week 52-78, as well as initial safety data and biopsy and efficacy results for three patients who received a 6E13 vg/kg dose (Cohort 2) as of the July 2025 data cut off. Key findings included:

- o TN-201 was generally well tolerated at both dose levels. No dose-limiting toxicities were observed, and all patients had successfully tapered off immunosuppressive medicine.
- o MyBP-C protein levels increased over time across patients in both Cohorts, with a substantial increase in protein levels observed commensurate with the higher dose in the first patient evaluable from Cohort 2.
- o Multiple parameters associated with risk of complications and/or survival improved among a majority of patients with greater than 26 weeks of follow-up, including circulating biomarkers of heart muscle injury and measures of hypertrophy. All patients with efficacy assessments improved to New York Heart Association Class I, indicating no limitations to daily living due to symptoms.
- o These data were presented at the *2025 American Heart Association Annual Scientific Sessions* and simultaneously published in *Cardiovascular Research*.
- In January, following implementation of modest protocol amendments in alignment with the U.S. Food and Drug Administration (FDA) input, Tenaya resumed enrollment in MyPEAK-1 to generate additional safety and efficacy data.
- Tenaya outlined anticipated milestones associated with the TN-201 program for 2026, which include:
 - o Enrolling additional patients in the 6E13 vg/kg expansion cohort of MyPEAK-1 over the course of the year
 - o Reporting interim MyPEAK-1 data for Cohort 2 and updates from Cohort 1 in the first half of 2026
 - o Presenting one-year Cohort 2 data and two-year Cohort 1 data in the second half of 2026
 - o Providing an update on its progress in pursuing regulatory alignment for TN-201 pivotal plans in the second half of the year.

TN-401 – Gene Therapy for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

- In December 2025, Tenaya reported positive initial data in the ongoing RIDGE-1 Phase 1b/2 clinical trial of TN-401 gene therapy for the potential treatment of ARVC caused by mutations in the *plakophilin-2(PKP2)* gene. The data reported included safety, biopsy and arrhythmia results from the first three patients to receive TN-401 at a dose of 3E13 vg/kg (Cohort 1) as of the October 2025 data cut off, with follow-up ranging from 20-40 weeks post-dose. Key findings included:
 - o TN-401 was generally well tolerated at the 3E13 vg/kg dose, and no dose-limiting toxicities were observed. Adverse events (AEs) were generally mild, asymptomatic and manageable and deemed unrelated to TN-401 treatment. Enrollment and dosing of Cohort 2 was completed with no new serious AEs reported.
 - o Biopsies taken at eight weeks post-treatment demonstrated robust transduction and RNA expression in all patients. PKP2 protein levels increased by an average of 10 percent compared to baseline in the first two patients dosed.
 - o Clinically meaningful improvements in measures of electrical instability (premature ventricular contractions and non-sustained ventricular tachycardias) were observed in the first two patients with greater than six months follow-up after TN-401 dosing.
-

- In January, the RIDGE-1 data and safety monitoring board (DSMB) reviewed all available data for the six patients to have received either a 3E13 vg/kg (Cohort 1) or 6E13 vg/kg (Cohort 2) dose of TN-401. The DSMB determined that TN-401 had an acceptable safety profile and endorsed continued enrollment of patients in RIDGE-1 expansion cohorts at either dose.
- In 2026, Tenaya expects to achieve the following milestones associated with the TN-401 program's advancement:
 - Enrolling patients in 6E13 vg/kg expansion cohort of RIDGE-1 throughout the year
 - Presenting one-year data for Cohort 1 and initial Cohort 2 data in the first half of 2026
 - Reporting interim Cohort 2 data in the second half of 2026
 - Pursuing regulatory alignment on TN-401 pivotal plans and sharing an update by year-end, as available.

TN-301 – Small Molecule HDAC6 Inhibitor for the Potential Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF) and Related Cardiac, Metabolic, or Muscular Diseases

- Tenaya presented encouraging preclinical data comparing TN-301, the company's highly selective HDAC6 inhibitor, with givinostat, an approved pan-HDAC inhibitor, in a well-established *mdx* mouse model of Duchenne muscular dystrophy (DMD) at the Muscular Dystrophy Association's 2026 Clinical and Scientific Congress.
- Results of the study showed that in *mdx* mice:
 - TN-301 treatment at doses as low as 3 mg/kg improved grip strength to wild-type levels within five weeks, whereas *mdx* mice treated with givinostat (10 mg/kg, approximating clinical exposures) failed to reach wild-type performance.
 - TN-301-mediated functional improvements were accompanied by reductions in circulating creatine kinase and favorable changes in gene expression, indicating reduced muscle cell injury.
 - In cardiomyocytes derived from human DMD-induced pluripotent stem cells, TN-301 corrected calcium handling abnormalities and mitochondrial dysfunction, while givinostat exacerbated these established drivers of DMD cardiomyopathy.
- In 2026, Tenaya plans to advance TN-301 toward clinical trials in patients in order to generate proof-of-activity data, with HFpEF and DMD being among the most promising potential indications identified to date.

Business Updates

- Tenaya entered into a multi-target research collaboration with Alnylam Pharmaceuticals to identify and validate novel genetic targets aimed at treating cardiovascular disease. Under the terms of the agreement, Tenaya will receive an upfront payment of up to \$10.0 million and may be eligible for development, regulatory and sales-based milestones totaling up to \$1.1 billion, in addition to reimbursement of associated research costs. Alnylam will be responsible for all development, manufacturing, regulatory and commercialization activities of therapeutics associated with the identified gene targets.
- In December 2025, Tenaya closed an underwritten public offering of 50,000,000 total units at a public offering price of \$1.20 per unit, consisting of one share of Tenaya common stock and one warrant to purchase one share of Tenaya common stock at an exercise price of \$1.50 per share, resulting in net proceeds of \$55.8 million.

Fourth Quarter and Full Year 2025 Financial Highlights

- **Cash Position and Guidance:** As of December 31, 2025, cash, cash equivalents and investments in marketable securities were \$100.5 million, as compared to \$61.4 million as of December 31, 2024. With the additional net proceeds of \$55.8 million from the December 2025 public offering after deducting underwriting discounts and commissions and offering expenses. Tenaya expects that such resources, along with the expected upfront payment from the Alnylam collaboration, will be sufficient to fund planned operations into the second half of 2027.
- **Research & Development (R&D) Expenses:** R&D expenses were \$14.8 million for the fourth quarter and \$68.6 million for the full year ended December 31, 2025, a decrease compared to R&D expenses of \$18.7 million and \$86.7 million for the same period in 2024. Non-cash stock-based compensation included in R&D expense was \$1.4 million for the fourth quarter and \$6.8 million for the full year ended December 31, 2025, compared to \$1.9 million and \$8.2 million for the same period in 2024.
- **General & Administrative (G&A) Expenses:** G&A expenses were \$6.0 million for the fourth quarter and \$24.7 million for the full year ended December 31, 2025, compared to \$6.0 million and \$29.2 million for the same period in 2024. Non-cash stock-based compensation included in G&A expense was \$1.3 million for the fourth quarter and \$6.2 million for the full year ended December 31, 2025, compared to \$1.8 million and \$8.3 million for the same period in 2024.
- **Net Loss:** Net loss was \$20.2 million, or \$0.12 loss per share, for the fourth quarter ended December 31, 2025, compared to a net loss of \$23.8 million, or \$0.28 per share, for the same period in 2024. For the full year 2025, net loss decreased to \$90.6 million, or \$0.59 per share, compared to a net loss of \$111.1 million, or \$1.31 per share, in 2024.

About Tenaya Therapeutics

Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya's pipeline includes clinical-stage candidates TN-201, a gene therapy for *MYBPC3*-associated hypertrophic cardiomyopathy (HCM) and TN-401, a gene therapy for *PKP2*-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). Tenaya has employed a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of novel medicines based on genetic insights, including TN-301, a clinical-stage small molecule HDAC6 inhibitor for the potential treatment of heart failure and related cardio/muscular disease, and multiple early-stage programs in preclinical development aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit www.tenayatherapeutics.com.

Forward Looking Statements

This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Words such as "planned," "potential," "anticipated," "expect," "plan," "anticipate," "eligible," and similar expressions are intended to identify forward-looking statements. Such forward-looking statements include, among other things, planned timing for sharing data from MyPEAK-1 and RIDGE-1 and the expected content of such data releases; the clinical, therapeutic and commercial potential of TN-201, TN-401 and TN-301; anticipated 2026 milestones for Tenaya's TN-201 and TN-401 programs, including enrollment, data announcements and regulatory alignment; the potential for new value drivers to arise from Tenaya's plans for TN-301 and collaboration activities; clinical development plans for TN-301; the potential for Tenaya to receive upfront, development, regulatory and sales-based milestone payments, as well as research reimbursement under the collaboration with Alnylam; the sufficiency of Tenaya's cash resources to fund the company into the second half of 2027; and statements made by Tenaya's chief executive officer. The forward-looking statements contained herein are based upon Tenaya's current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including but not limited to: availability of data at the referenced times; the timing and progress of Tenaya's clinical trials; unexpected concerns that may arise as a result of the occurrence of adverse safety events in Tenaya's

clinical trials; the potential failure of Tenaya's product candidates to demonstrate safety and/or efficacy in clinical testing; the potential for any clinical trial results to differ from preclinical, interim, preliminary, topline or expected results; risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early stage company; Tenaya's ability to develop, initiate or complete preclinical studies and clinical trials, and obtain approvals, for any of its product candidates; Tenaya's ability to achieve the expected benefits from the collaboration with Alnylam; the occurrence of any event, change or other circumstance that could give rise to the termination of the collaboration with Alnylam; Tenaya's continuing compliance with applicable legal and regulatory requirements; regulatory developments in the United States and foreign countries; Tenaya's ability to raise any additional funding it will need to continue to pursue its business and product development plans; Tenaya's reliance on third parties; Tenaya's manufacturing, commercialization and marketing capabilities and strategy; the loss of key scientific or management personnel; competition in the industry in which Tenaya operates; Tenaya's ability to comply with specified operating covenants and restrictions in its loan agreement; Tenaya's ability to obtain and maintain intellectual property protection for its product candidates and platform technology; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled "Risk Factors" in documents that Tenaya files from time to time with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and Tenaya assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Tenaya Contacts

Michelle Corral
VP, Corporate Communications and Investor Relations
IR@tenayathera.com

Investors

Anne-Marie Fields
Precision AQ
annemarie.fields@precisionaq.com

Media

Wendy Ryan
Ten Bridge Communications
wendy@tenbridgecommunications.com

TENAYA THERAPEUTICS, INC.

Condensed Statements of Operations
(In thousands, except share and per share data)
(Unaudited)

	Three Months Ended December 31,		Year Ended December 31,	
	2025	2024	2025	2024
Operating expenses:				
Research and development	\$ 14,798	\$ 18,688	\$ 68,607	\$ 86,742
General and administrative	5,977	5,964	24,724	29,206
Total operating expenses	<u>20,775</u>	<u>24,652</u>	<u>93,331</u>	<u>115,948</u>
Loss from operations	(20,775)	(24,652)	(93,331)	(115,948)
Other income, net:				
Interest income	575	812	2,682	4,737
Other income, net	25	4	52	82
Total other income, net	<u>600</u>	<u>816</u>	<u>2,734</u>	<u>4,819</u>
Net loss before income tax expense	(20,175)	(23,836)	(90,597)	(111,129)
Income tax expense	—	—	—	—
Net loss	<u>\$ (20,175)</u>	<u>\$ (23,836)</u>	<u>\$ (90,597)</u>	<u>\$ (111,129)</u>
Net loss per share, basic and diluted	<u>\$ (0.12)</u>	<u>\$ (0.28)</u>	<u>\$ (0.59)</u>	<u>\$ (1.31)</u>
Weighted-average shares used in computing net loss per share, basic and diluted	<u>175,047,948</u>	<u>86,162,841</u>	<u>152,971,259</u>	<u>84,822,468</u>

Condensed Balance Sheet Data
(In thousands)
(Unaudited)

	December 31,	
	2025	2024
Cash, cash equivalents and marketable securities	\$ 100,547	\$ 61,446
Total assets	\$ 146,921	\$ 119,940
Total liabilities	\$ 23,656	\$ 27,086
Total liabilities and stockholders' equity	\$ 146,921	\$ 119,940

